Homepage2096 • HKG
add
Simcere Pharmaceutical Group Ltd
Vorige slotkoers
$Â 5,75
Dag-range
$Â 5,62 - $Â 5,74
Jaar-range
$Â 4,94 - $Â 8,73
Beurswaarde
14,88Â mld. HKD
Gem. volume
5,96Â mln.
Koers/winst
19,25
Dividendrendement
3,05%
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(CNY) | dec 2023info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,61Â mld. | -10,92% |
Bedrijfskosten | 1,04Â mld. | -21,20% |
Netto inkomsten | -779,94Â mln. | -279,90% |
Netto winstmarge | -48,32 | -302,01% |
Winst per aandeel | — | — |
EBITDA | 228,57Â mln. | 38,19% |
Effectief belastingtarief | 1,59% | — |
Balans
Totale activa
Totale passiva
(CNY) | dec 2023info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 2,02Â mld. | -23,04% |
Totale activa | 10,85Â mld. | 0,60% |
Totale passiva | 3,63Â mld. | -0,28% |
Totaal aandelenvermogen | 7,22 mld. | — |
Uitstaande aandelen | 2,62 mld. | — |
Koers-boekwaardeverhouding | 2,08 | — |
Rendement op activa | 4,05% | — |
Rendement op kapitaal | 5,09% | — |
Kasstroom
Nettomutatie in liquide middelen
(CNY) | dec 2023info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -779,94Â mln. | -279,90% |
Operationele kasstroom | 116,54Â mln. | -65,16% |
Kasstroom uit beleggingen | -132,15Â mln. | 38,57% |
Kasstroom uit financiering | -205,24Â mln. | 10,81% |
Nettomutatie in liquide middelen | -219,92Â mln. | -111,42% |
Vrije kasstroom | -219,74Â mln. | -114,10% |
Over
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
CEO
Opgericht
1995
Hoofdvestiging
Website
Werknemers
7.027